| 注册
首页|期刊导航|临床肝胆病杂志|恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的疗效观察

恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的疗效观察

张文 余建国 朱贵忠 赵詹东 王晓伟

临床肝胆病杂志Issue(11):1169-1172,4.
临床肝胆病杂志Issue(11):1169-1172,4.DOI:10.3969/j.issn.1001-5256.2014.11.019

恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的疗效观察

Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load

张文 1余建国 1朱贵忠 2赵詹东 1王晓伟1

作者信息

  • 1. 襄阳市第一人民医院 肝病内科,湖北 襄阳441000
  • 2. 襄阳市第一人民医院 检验科,湖北 襄阳441000
  • 折叠

摘要

Abstract

Objective To investigate the efficacy and safety of entecavir (ETV)combined with adefovir (ADV)in chronic hepatitis B (CHB)patients with high viral load.Methods Eighty CHB patients with high viral load who were admitted to our hospital from December 2008 to December 201 1 were equally and randomly divided into observation group and control group.The control group was given ETV,while the observation group was treated with ETV combined with ADV.HBV DNA load,HBsAg or HBeAg seroconversion,alanine aminotransferase (ALT)normalization,and adverse reactions before and after 3,6,12,and 24 months of treatment were evaluated.Comparison of continuous data between the two groups was made by independent-samples t test,and comparison of categorical data was made by chi-square test.Re-sults Compared with the control group,the observation group had significantly lower HBV DNA load after 6,12,and 24 months of treatment (3.7 ±0.3 vs 3.4 ±0.4 log copies/ml,t=3.339,P<0.05;2.9 ±0.4 vs 2.6 ±0.3 log copies/ml,t=5.657,P<0.05;1.6 ±0.7 vs 1.2 ± 0.4 log copies/ml,t=2.806,P<0.05 ).The HBV DNA clearance rate and HBeAg clearance rate in observation group were significantly higher than those in control group after 12 months of treatment (87.5%vs 70.0%,P<0.05;80.0%vs 55.0%,P<0.05)and 24 months of treatment (95.0%vs 77.5%,P<0.05;90.0%vs 70.0%,P<0.05).The observation group had significantly higher HBeAg seroconversion rate and ALT normalization rate than the control group after 24 months of treatment (77.5% vs 50.0%,P<0.05;82.5% vs 55.0% P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05),but the observation group had a significantly lower viral breakthrough rate than the control group (0 vs 10.0%,P<0.05).Conclusion For CHB patients with high viral load,ETV combined with ADV has strong antiviral activity,reduces drug resistance and poor response,and shows bet-ter long-term clinical efficacy than ETV alone,suggesting that it is a safe and reliable therapy.

关键词

肝炎,乙型,慢性/药物疗法,联合/恩替卡韦/阿德福韦酯

Key words

hepatitis B,chronic/drug therapy,combination/entecavir/adefovir

分类

医药卫生

引用本文复制引用

张文,余建国,朱贵忠,赵詹东,王晓伟..恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的疗效观察[J].临床肝胆病杂志,2014,(11):1169-1172,4.

临床肝胆病杂志

OACSTPCD

1001-5256

访问量0
|
下载量0
段落导航相关论文